KENILWORTH (NJ) (dpa-AFX) - Astellas Pharma Inc. (ALPMY, ALPMY) announced
the submission of a Supplemental New Drug Application or sNDA to Japan's
Ministry of Health, Labour and Welfare for PADCEV with KEYTRUDA as a combination
therapy for the first-line treatment of adult patients with previously untreated
locally advanced or metastatic urothelial cancer.

If approved, PADCEV with KEYTRUDA has the potential to change the treatment
paradigm, becoming the first combination treatment to offer an alternative to
platinum-containing chemotherapy, the current standard of care in first-line
locally advanced or metastatic urothelial cancer, Astellas said in a statement.

The Committee for Medicinal Products for Human Use of the European Medicines
Agency is also reviewing the combination therapy. The U.S. Food and Drug
Administration approved the combination therapy in December 2023.

For More Such Health News, visit rttnews.com



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX